ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Acquired by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P increased its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 11.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 194,185 shares of the specialty pharmaceutical company’s stock after acquiring an additional 19,568 shares during the period. Loomis Sayles & Co. L P owned approximately 0.92% of ANI Pharmaceuticals worth $10,735,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Thrivent Financial for Lutherans lifted its stake in ANI Pharmaceuticals by 2.3% in the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after acquiring an additional 299 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of ANI Pharmaceuticals during the 3rd quarter worth $751,000. Charles Schwab Investment Management Inc. grew its stake in shares of ANI Pharmaceuticals by 3.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 250,346 shares of the specialty pharmaceutical company’s stock worth $14,936,000 after purchasing an additional 8,869 shares in the last quarter. Bank of Montreal Can acquired a new position in shares of ANI Pharmaceuticals during the third quarter worth $13,043,000. Finally, FMR LLC increased its holdings in ANI Pharmaceuticals by 27.5% in the third quarter. FMR LLC now owns 18,401 shares of the specialty pharmaceutical company’s stock valued at $1,098,000 after buying an additional 3,972 shares during the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price objective for the company. Leerink Partners initiated coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target for the company. StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, March 14th. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Finally, Guggenheim lifted their price target on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $79.75.

ANI Pharmaceuticals Trading Down 1.1 %

Shares of ANI Pharmaceuticals stock opened at $67.61 on Friday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The company has a market capitalization of $1.47 billion, a P/E ratio of -122.93 and a beta of 0.63. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $70.00. The company’s fifty day moving average is $60.49 and its two-hundred day moving average is $58.39.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $60.20, for a total transaction of $60,200.00. Following the completion of the sale, the senior vice president now directly owns 68,624 shares of the company’s stock, valued at $4,131,164.80. This represents a 1.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the transaction, the vice president now owns 80,545 shares in the company, valued at $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 3,200 shares of company stock worth $191,776. Company insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.